89R28276 CJD-F
By: Parker, et al.
S.B. No. 2308
(Harris, Leach, Phelan, Orr, VanDeaver, et al.)
Substitute the following for S.B. No. 2308: No.
A BILL TO BE ENTITLED
AN ACT
relating to the establishment of a grant programconsortium to fund theconduct United
States Food and Drug Administration's drug development trials withclinical
trials with ibogaine forto the purpose of securingsecure the administration's approval of the
asmedication's a medicationuse for treatment of opioid use disorder, co-occurring
substance use disorder, and any other neurological or mental health
conditions for which ibogaine demonstrates efficacy. and to the
administration of that treatment.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
SECTION 1. Subtitle C, Title 6, Health and Safety Code, is
amended by adding Chapter 491 to read as follows:
CHAPTER 491. GRANTIBOGAINE PROGRAM FOR DRUG DEVELOPMENT OF IBOGAINETREATMENT
TREATMENT
SUBCHAPTER A. GENERAL PROVISIONS
Sec. 491.001. DEFINITIONS. In this chapter:
(1) "Commission" means the Health and Human Services
Commission.
(2) "Executive commissionerComptroller" means the executivecomptroller of public
commissioner of the Health and Human Services Commission.
Sec. 491.002. RULES. The executive commissioner shall
adopt rules necessary to administer this chapter.
Sec. 491.003. ESTABLISHMENT OF GRANT PROGRAM. The
commission shall establish and administer a grant program to fund a
public-private partnership program that will pay for the costs of
the United States Food and Drug Administration's drug development
trials with ibogaine to secure the administration's approval as a
medication for treatment of opioid use disorder, co-occurring
substance use disorder, and any other neurological or mental health
conditions for which ibogaine demonstrates efficacy.
Sec. 491.004. APPLICATION. (a) The commission shall
prepare and issue a notice of funding opportunity to solicit
applications for the grant program established under this chapter.
(b) An applicant may apply to the commission in the form and
manner prescribed by the commission for a grant under this chapter.
To be eligible for a grant, an applicant must:
(1) be a for-profit, nonprofit, or public benefit
corporate entity that has the requisite organizational and
financial capacity to:
(A) conduct the United States Food and Drug
accounts.
(3) "Drug developer" means a pharmaceutical company,
biotechnology company, or contract development and manufacturing
Administration'sorganization engaged in drug development trialsand with ibogaine to securemanufacturing.
the administration's approval as a medication for treatment of
opioid use disorder, co-occurring substance use disorder, and any
other neurological or mental health conditions for which ibogaine
demonstrates efficacy;
(B) as a result of the data obtained from the drug
development trial described by Paragraph (A), seek United States
Food and Drug Administration approval of ibogaine; and
(C) conduct future drug development trials of
ibogaine as a medication for treatment of opioid use disorder,
co-occurring substance use disorder, and any other neurological or
mental health conditions for which ibogaine demonstrates efficacy;
and
(2) provide:
(A) a detailed description of the planned
strategy for obtaining approval for the drug development trial from
(4) "Hospital" has the meaning assigned by Section
241.003.
(5) "Ibogaine" means ibogaine and ibogaine-based
therapeutics, including ibogaine analogs.
(6) "Institution of higher education" has the meaning
assigned by Section 61.003, Education Code.
SUBCHAPTER B. DRUG DEVELOPMENT OF IBOGAINE TREATMENT
Sec. 491.051. ESTABLISHMENT OF CONSORTIUM. (a) A
consortium may be established under this section and apply for
commission selection under this subchapter to conduct drug
development clinical trials with ibogaine and secure the United
States Food and Drug Administration's approval of ibogaine as a
medication for the treatment of:
(1) opioid use disorder;
(2) co-occurring substance use disorder; and
(3) any other neurological or mental health condition
for which ibogaine demonstrates efficacy.
(b) A consortium established under this section must
include one or more of each of the following entities:
(1) a drug developer;
(2) an institution of higher education; and
(3) a hospital.
Sec. 491.052. LEAD INSTITUTION; ADMINISTRATION; PERSONNEL.
(a) A consortium established under this subchapter shall select a
lead institution of higher education from among the consortium's
members to represent the consortium and perform administrative
functions under this subchapter, including contracting with and
reporting to the commission as required by this subchapter.
(b) A consortium selected by the commission under this
subchapter may employ personnel, including clinical,
administrative, and data management personnel, necessary to
support any consortium member's activities related to drug
development clinical trials conducted under this subchapter.
Sec. 491.053. CONSORTIUM PROPOSAL. (a) The lead
institution of higher education of a consortium shall submit to the
commission a proposal and request for funding on behalf of the
consortium for purposes of conducting ibogaine drug development
clinical trials in accordance with this subchapter.
(b) A proposal submitted under Subsection (a) must provide:
(1) the identity of all consortium members;
(2) a detailed description of the planned strategy for
obtaining approval for the drug development clinical trials from
the United States Food and Drug Administration;
(B3) a detailed drug development clinical trial design that
that includes:
(iA) a description of the composition of the
applicant'sconsortium's drug development clinical trial team and the expertise of the
of the team members;
(iiB) a drug development clinical trial participant
participant recruitment plan;
(iiiC) detailed patient screening criteria and cardiac
and cardiac safety protocols;
(ivD) administration protocols;
(vE) an aftercare and post-acute treatment
support plan; and
(viF) a data integrity plan;
(4) a detailed plan to seek a breakthrough therapy
designation for ibogaine from the United States Food and Drug
Administration under 21 U.S.C. Section 356;
(C5) a proposal to recognize this state's commercial
commercial interest in all patentable intellectual property that may be generated over
may be generated over the course of the drug development clinical trials, including:
including:
(iA) the treatment that is the subject of the
trials;
(iiB) administration protocols;
(iiiC) treatment models or techniques; and
(ivD) technology used in the trials;
(D6) a plan to establish a corporate presence in this
this state and to promote and maintain ibogaine-related biomedical
research, development, treatment, manufacturing, and distribution
in this state;
(E7) a plan to secure third-party payor approval for
for ibogaine treatment following approval by the United States Food and
and Drug Administration through:
(iA) private insurers;
(iiB) Medicare;
(iiiC) Medicaid; and
(ivD) the TRICARE program of the United States
States Department of Defense;
(F8) a plan to ensure ibogaine treatment access to
uninsured individuals following approval by the United States Food
and Drug Administration;
(G9) a plan to train and credential medical providers
providers to administer ibogaine treatment according to developed clinical
clinical standards; and
(H10) financial disclosures that verify the
applicant'sconsortium's capacity to fully match state funding. with funds
(c) The commission shall:
(1) make available the application required under this
section; and
(2) announce a period of not less than 90 days during
which applicants may submit an application under this chapter.
received from non-state sources.
Sec. 491.005054. COMMISSION SELECTION COMMITTEE. (a) The commission, in the
shall create a selection committee and select the number of
members. The committee must be composed of:
(1) subject matter experts;
(2) philanthropic partners; and
(3) legislative designees.
(b) The selection committee shall review applications,
communicate supplemental inquiries to applicants, and recommend to
commission's sole discretion, shall select a consortium
established in accordance with Section 491.051 for the purpose of
conducting ibogaine drug development clinical trials under this
subchapter.
Sec. 491.055. CONTRACT WITH LEAD INSTITUTION. (a) As soon
as practicable after selecting a consortium to conduct ibogaine
drug development clinical trials under Section 491.054, the
the commission theshall bestenter applicantsinto toan conductinteragency thecontract, drugas developmentprovided by
Chapter 771, Government Code, with the lead institution of higher
education of the selected consortium to provide funding to
implement the consortium's proposed ibogaine drug development
clinical trials.
(c) The commission shall consider the recommendations of
(b) The interagency contract described by Subsection (a)
must specify:
(1) the goals and objectives of the proposed ibogaine
drug development clinical trials;
(2) the proposed budget;
the selection committee in selecting(3) the applicanttimeline tofor conductcompleting the proposed
objectives;
(4) the for-profit, nonprofit, or public benefit
corporate entities collaborating with the consortium in the drug
development clinical trials under this subchapter;
(5) the percentage of the revenue arising from the
ibogaine drug development trial.clinical trials to be paid to the state; and
Sec. 491.006. INVESTIGATIONAL NEW DRUG APPLICATION. On
notification(6) fromany other information required by the commission that the applicant was selected to.
conduct the ibogaine drug development trial, the applicant shall,
as(c) As soon as practicable: after entering into an
interagency contract under Subsection (a), the commission shall
report the existence of the contract to the legislature.
(d) The commission may not disburse funds to or for a
selected consortium under the interagency contract described by
Subsection (a) until the consortium receives and the commission
verifies the receipt of matching funds from sources other than the
state.
Sec. 491.056. INVESTIGATIONAL NEW DRUG APPLICATION. On the
commission's notification that a consortium is selected to conduct
the drug development clinical trials under this subchapter, a drug
developer or hospital member of the selected consortium or the lead
institution of higher education of the consortium, as specified by
written agreement of the consortium members, shall, as soon as
practicable:
(1) submit an investigational new drug (IND)
application withto the United States Food and Drug Administration in
accordance with 21 C.F.R. Part 312; and
(2) seek a breakthrough therapy designation for
ibogaine from the United States Food and Drug Administration under
21 U.S.C. Section 356.
Sec. 491.007057. ESTABLISHMENT OF DRUG DEVELOPMENT CLINICAL TRIAL SITES. For
SITES. On approval of the applicant's investigational new drug
application by the United States Food and Drug Administration, the
commission shall, in consultation with the applicant, establish
drug development trial sites that must be equipped and staffed to
provide cardiac intensive care services to patients.
purposes of conducting a drug development clinical trial under this
subchapter, only an institution of higher education or a hospital
may serve as a trial site.
Sec. 491.008058. CONDUCTINGFUNDING; DRUGDISBURSEMENT DEVELOPMENTBY TRIALCOMMISSION. (a) As
The commission and consortium members may solicit and accept gifts,
grants, and donations of any kind received from sources other than
soonthe asstate practicablefor afterpurposes of funding drug development trialclinical sites aretrials
established under Section 491.007, the applicant shall begin a drug
development trial to administer treatment with ibogaine.
(b) The commission, in consultation with the selection
committee under Section 491.005, shall select an institutional
review board with a presence in this state to oversee and verify the
drug development trial research activity for scientific validation
and authentication under the requirements of the United States Food
and Drug Administration.
(c) The applicant shall request the designation under 21
under this subchapter.
(b) Disbursements of funds by the commission may be made
incrementally based on the completion of clearly defined objectives
as negotiated in the contract described by Section 491.055,
including verifiable documentation demonstrating the efficient
expenditure of both state and matching funds.
Sec. 491.059. REPORTING REQUIREMENTS. (a) A consortium
U.S.C.selected Sectionto 356conduct during theibogaine drug development trialclinical iftrials theshall
ibogaine treatment is demonstrating efficacy.
Sec. 491.009. FUNDING. (a) The commission may use money
appropriated to the commission and money received as a gift, grant,
or donation to pay for a grant under this chapter. The commission
may solicit and accept gifts, grants, and donations of any kind and
from any source for purposes of this section.
quarterly prepare and submit to the commission:
(b1) Ana applicantreport selectedon tothe performprogress aof the drug development
clinical trials conducted under this subchapter; and
(2) a financial status report, including information
to verify expenditures of state funds and required matching funds.
(b) The commission shall submit a report to the legislature
on the progress of the drug development clinical trials conducted
trial under this chaptersubchapter shallnot contributelater towardthan theDecember cost1 of each year.
developing the ibogaine treatment an amount of money that is at
least equal to the amount of money that the applicant received in
the form of a grant from the commission.
SECTION 2. If before implementing any provision of this Act
a state agency determines that a waiver or authorization from a
Sec. 491.060. ALLOCATION OF REVENUE ATTRIBUTABLE TO
INTELLECTUAL PROPERTY AND OTHER RIGHTS. (a) The revenue
attributable to all intellectual property rights and other
commercial rights arising from drug development clinical trials
conducted by a consortium under this subchapter during the period
for which the trials are funded and any following period of
commercialization shall be allocated as follows:
(1) not less than 20 percent to the state as specified
in the contract under Section 491.055; and
(2) the remainder to the members of the consortium in
the amounts specified by written agreement of the members.
(b) For purposes of this section, intellectual property
rights and other commercial rights arising from the drug
development clinical trials conducted under this subchapter
include any of the following as related to the trials:
(1) intellectual property, technology, and
inventions;
(2) patents, trademarks, and licenses;
(3) proprietary and confidential information;
(4) trade secrets, data, and databases;
(5) tools, methods, and processes;
(6) treatment models or techniques;
(7) administration protocols; and
(8) works of authorship.
Sec. 491.061. USE OF STATE REVENUE. (a) The comptroller
shall deposit the revenue received under Section 491.060 to the
credit of the general revenue fund.
(b) Of the amount deposited under Subsection (a), 25 percent
may be appropriated only to programs that assist veterans in this
state.
(c) The comptroller shall develop accounting procedures for
the purpose of implementing this section.
SUBCHAPTER C. IBOGAINE TREATMENT ADMINISTRATION
Sec. 491.101. APPLICABILITY. This subchapter applies only
if ibogaine is approved by the United States Food and Drug
Administration to treat a medical condition.
Sec. 491.102. MEDICAL SUPERVISION. A physician licensed
under Subtitle B, Title 3, Occupations Code, who has prescribed
ibogaine for a patient shall supervise the administration of
ibogaine at a hospital or other licensed health care facility to
ensure the patient's safety while the patient is under the
influence of ibogaine.
Sec. 491.103. ADMINISTRATION UNDER FEDERAL LAW. This
subchapter does not preclude a physician from administering
ibogaine in accordance with federal law.
SECTION 2. (a) If before implementing any provision of this
Act a state agency determines that a waiver or authorization from a
federal agency is necessary for implementation of that provision,
the agency affected by the provision shall request the waiver or
authorization and may delay implementing that provision until the
waiver or authorization is granted.
(b) The Health and Human Services Commission shall begin
accepting proposals from consortiums under Chapter 491, Health and
Safety Code, as added by this Act, not later than the 60th day after
the effective date of this Act.
SECTION 3. This Act takes effect immediately if it receives
3 párrafos sin cambios
a vote of two-thirds of all the members elected to each house, as
provided by Section 39, Article III, Texas Constitution. If this
Act does not receive the vote necessary for immediate effect, this
Act takes effect September 1, 2025.
______________________________
______________________________
President of the Senate
Speaker of the House
I hereby certify that S.B. No. 2308 passed the Senate on
April 30, 2025, by the following vote: Yeas 26, Nays 5;
May 15, 2025, Senate refused to concur in House amendments and
requested appointment of Conference Committee; May 20, 2025, House
granted request of the Senate; May 31, 2025, Senate adopted
Conference Committee Report by the following vote: Yeas 27,
Nays 4.
______________________________
Secretary of the Senate
I hereby certify that S.B. No. 2308 passed the House, with
amendments, on May 13, 2025, by the following vote: Yeas 138,
Nays 2, two present not voting; May 20, 2025, House granted request
of the Senate for appointment of Conference Committee;
June 1, 2025, House adopted Conference Committee Report by the
following vote: Yeas 134, Nays 4, one present not voting.
______________________________
Chief Clerk of the House
Approved:
______________________________
Date
______________________________
Governor